Market Research Logo

Liquid Biopsy Market: Global Industry Analysis and Opportunity Assessment 2016-2026

Liquid Biopsy Market: Global Industry Analysis and Opportunity Assessment 2016-2026

This report by Future Market Insights (FMI) examines the ‘Liquid Biopsy Market’ for the period 2016–2026. The primary objective of the report is to offer updates and information related to market opportunities in the global liquid biopsy market.

Report Description

The global liquid biopsy market report begins by defining liquid biopsy and various types of markers used in liquid biopsy. It is followed by an overview of market dynamics of the global liquid biopsy market, which includes FMI’s analysis of key trends, drivers, restraints and opportunities, and reimbursement scenario that is influencing the growth of the liquid biopsy market. It also includes an insight into case-studies and product pipeline. Impact analysis of key growth drivers and restraints based on a weighted average model have been included in the global liquid biopsy market report after detailed analysis of individual regions to better equip readers with meaningful insights on ongoing developments in the oncology market.

The primary factors fuelling demand for liquid biopsy diagnostic tests are growing incidences of lung, gastrointestinal and breast cancer. Other factors driving demand for liquid biopsy tests are increasing inclination of oncologists and physician to opt for non-invasive diagnostic procedures, reluctance of the patients to go painful biopsies and increase in the demand of personalized medicine. Whereas increasing number of test launches and entry of regional players also drives the market for liquid biopsy tests. However, a primary factor hampering growth of the liquid biopsy market is its penetration owing lower awareness of blood tests to detect cancer.

Based on market type, the market has been segmented into circulating tumour cells (CTCs), Circulating tumour Nucleic Acids (ctNA) and exosomes. A detailed analysis has been provided for these segment in terms of market size, Y-o-Y growth rate, absolute $ opportunity and BPS analysis.

Based on sample type, the market has been segmented into blood, urine and others (plasma, saliva, CSF). Our analysis predicts that biopsies through blood samples would increase at a very fast pace, increasing the number of blood diagnostic test to detect cancer is expected to contribute significantly to increasing demand for liquid biopsies the forecast period.

Based on the disease indication the liquid biopsy market has been segmented into lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, colorectal cancer, leukemia and others. Lung cancer is expected to expand at a higher CAGR, due to increasing prevalence of lung cancer over the forecast period. Further, based on end-user segmentation, the market is segmented into hospitals, cancer institutes, academic institutes and diagnostic centres. Increasing commercialization of liquid biopsy test is expected to increase the revenue generation of liquid biopsies from hospitals and diagnostic centres surgery. This trend is expected to be particularly prominent in countries where access to healthcare services is increasing especially in APEJ

The next section of the report highlights liquid biopsy market by region and provides market outlook for 2016–2026. The report also discusses key regional trends contributing to the revenue growth of the liquid biopsy tests worldwide, as well as analyses the impact of drivers and restraints in each region. Key regions assessed in this report include North America, Latin America, Western Europe, Eastern Europe, Asia Pacific Excluding Japan (APEJ), Japan and Middle East & Africa (MEA).

The above sections—by marker type, sample type, disease indication, end users and region—evaluate the present scenario and growth prospects of the liquid biopsy tests market for 2016–2026. We have considered 2015 as the base year and provided data for the forecast period, i.e., 2016–2026.

To ascertain liquid biopsy tests market size, we have also considered revenue generated by companies in liquid biopsy market space. The forecast presented here assesses the total revenue by value across the liquid biopsy market. In order to offer an accurate forecast, we started by sizing up the current market, which forms the basis of how the liquid biopsy market is expected to develop in the future. Given the characteristics of the market, we triangulated the outcome of three different types of analysis based on supply side, downstream industry demand, and the economic envelope.

In addition, it is imperative to note that in an ever-fluctuating global economy, we not only conduct forecasts in terms of CAGR, but also analyse it based on key parameters such as year-on-year (Y-o-Y) growth rates to understand the predictability of the market, and to identify the right opportunities across the global liquid biopsy market.

The liquid biopsy market segments in terms of marker type, sample type, disease indication, end user, and regions. These segments are analysed in terms of Basis Point Share (BPS) to understand individual segment’s relative contributions to market growth. This detailed level of information is important for identifying various key trends in the liquid biopsy market.

Another key feature of this report is the analysis of key segments in terms of absolute dollar opportunity. This is overlooked while forecasting the market. However, absolute dollar opportunity is critical for assessing the level of opportunity that a provider can look to achieve, as well as to identify potential resources from a sales and delivery perspective, in the global liquid biopsy market.

To understand key growth segments in terms of growth and adoption for liquid biopsy tests globally, Future Market Insights developed the liquid biopsy market ‘Attractiveness Index’. The resulting index is expected to help providers identify real market opportunities in the overall oncology market.

In the final section of the report on the global liquid biopsy market, ‘Competitive Landscape’ is included to provide report audiences with a dashboard view, based on categories of test developers in the liquid biopsy market space and key differentiators. Key categories of providers covered in the report are companies developing liquid biopsy tests. This section is primarily designed to provide clients with an objective and detailed comparative assessment of key providers specific to a market segment in the liquid biopsy value chain and the potential players for the same. Report audiences can gain segment-specific company insights to identify and evaluate key competitors based on in-depth assessment of capabilities and successes in liquid biopsy marketplace.

Detailed profiles of the liquid biopsy tests developing companies are also included in the scope of the report to evaluate their long- and short-term strategies, key offerings, SWOT analysis, and recent developments in the global liquid biopsy market.

Key competitors covered in terms of liquid biopsy test developing companies BIOCEPT, INC., Qiagen N.V., Trovagene, Inc., Janssen Global Services, LLC, MDxHealth SA, Natera, Inc., F. Hoffmann-La Roche Ltd., Silicon Biosystems, Pathway Genomics Corporation, Sysmex Corporation.

Key Segments Covered

By Marker Type
CTCs (Circulating tumour Cells)
ctNA (Circulating tumour Nucleic Acids)
Exosomes

By Sample Type
Blood
Urine
Others (Plasma, Saliva, CSF)

By Disease Indication
Lung Cancer
Gastrointestinal Cancer
Prostate Cancer
Breast Cancer
Colorectal Cancer
Leukemia
Others

By End-User
Hospitals
Cancer Institutes
Academic Institutes
Diagnostic Centers

Key Regions/Countries Covered

North America
U.S.
Canada

Latin America
Brazil
Mexico
Rest of Latin America

Western Europe
U.K.
Germany
France
Spain
Italy
Nordic
BENELUX
Rest of Western Europe

Eastern Europe
Russia
Poland
Rest of Eastern Europe

Asia Pacific Ex. Japan (APEJ)
China
India
Australia and New Zealand
ASEAN
Rest of APAC

Japan

Middle East & Africa
GCC
South Africa
Rest of MEA

Key Companies

BIOCEPT, INC.
Qiagen N.V.
Trovagene, Inc.
Janssen Global Services, LLC
MDxHealth SA
Natera, Inc.
Hoffmann-La Roche Ltd.
Silicon Biosystems
Pathway Genomics Corporation
Sysmex Corporation


1. Executive Summary
2. Assumptions and Acronyms
3. Research Methodology
4. Liquid Biopsy Market Overview
4.1. Introduction
4.1.1. Liquid Biopsy Market Definition
4.1.2. Liquid Biopsy Market Taxonomy
4.2. Liquid Biopsy Market Dynamics
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunity
4.3. Regional Cancer Epidemiology
4.4. Reimbursement Scenario
4.5. Pipeline Assessment, By Products
4.6. Product Penetration and Pricing Impact
4.7. Revenue Potential Liquid Biopsy
4.8. Case Studies
5. Global Liquid Biopsy Market Forecast
5.1. Market Value (US$ Mn) Forecast
5.1.1. Y-o-Y Growth Projections
5.1.2. Absolute $ Opportunity
5.2. Liquid Biopsy Market Trends
5.3. Global Liquid Biopsy Market Snapshot (2015)
5.3.1. Market Share, By Sample Type
5.3.2. Market Share, By Disease Indication
5.3.3. Market Share, By Marker Type
5.3.4. Market Share, By End User
6. Global Liquid Biopsy Market Analysis, By Sample Type
6.1. Introduction
6.1.1. Y-o-Y Growth Comparison, By Sample Type
6.1.2. Market Share & Basis Point (BPS) Analysis, By Sample Type
6.2. Market Forecast, By Sample Type
6.2.1. Blood
6.2.1.1. Absolute $ Opportunity
6.2.1.2. Market Value (US$ Mn) Forecast
6.2.2. Urine
6.2.2.1. Absolute $ Opportunity
6.2.2.2. Market Value (US$ Mn) Forecast
6.2.3. Others (Plasma, Saliva, CSF)
6.2.3.1. Absolute $ Opportunity
6.2.3.2. Market Value (US$ Mn) Forecast
6.3. Market Attractiveness Analysis, By Sample Type
7. Global Liquid Biopsy Market Analysis, By Marker Type
7.1. Introduction
7.1.1. Y-o-Y Growth Comparison, By Marker Type
7.1.2. Market Share & Basis Point (BPS) Analysis, By Marker Type
7.2. Market Forecast, By Marker Type
7.2.1. CTCs (circulating tumor cells)
7.2.1.1. Absolute $ Opportunity
7.2.1.2. Market Value (US$ Mn) Forecast
7.2.2. ctNA (circulating tumor nucleic acids)
7.2.2.1. Absolute $ Opportunity
7.2.2.2. Market Value (US$ Mn) Forecast
7.2.3. Exosomes
7.2.3.1. Absolute $ Opportunity
7.2.3.2. Market Value (US$ Mn) Forecast
7.3. Market Attractiveness Analysis, By Marker Type
8. Global Liquid Biopsy Market Analysis, By End User
8.1. Introduction
8.1.1. Y-o-Y Growth Comparison, By End User
8.1.2. Market Share & Basis Point (BPS) Analysis, By End User
8.2. Market Forecast, By End User
8.2.1. Hospitals
8.2.1.1. Absolute $ Opportunity
8.2.1.2. Market Value (US$ Mn) Forecast
8.2.2. Academic Institutes
8.2.2.1. Absolute $ Opportunity
8.2.2.2. Market Value (US$ Mn) Forecast
8.2.3. Cancer Institutes
8.2.3.1. Absolute $ Opportunity
8.2.3.2. Market Value (US$ Mn) Forecast
8.2.4. Diagnostic Centers
8.2.4.1. Absolute $ Opportunity
8.2.4.2. Market Value (US$ Mn) Forecast
8.3. Market Attractiveness Analysis, By End User
9. Global Liquid Biopsy Market Analysis, By Disease Indication
9.1. Introduction
9.1.1. Y-o-Y Growth Comparison, By Disease Indication
9.1.2. Market Share & Basis Point (BPS) Analysis, By Disease Indication
9.2. Market Forecast, By Disease Indication
9.2.1. Lung Cancer
9.2.1.1. Absolute $ Opportunity
9.2.1.2. Market Value (US$ Mn) Forecast
9.2.2. Leukemia
9.2.2.1. Absolute $ Opportunity
9.2.2.2. Market Value (US$ Mn) Forecast
9.2.3. Gastrointestinal Cancer
9.2.3.1. Absolute $ Opportunity
9.2.3.2. Market Value (US$ Mn) Forecast
9.2.4. Breast Cancer
9.2.4.1. Absolute $ Opportunity
9.2.4.2. Market Value (US$ Mn) Forecast
9.2.5. Prostate Cancer
9.2.5.1. Absolute $ Opportunity
9.2.5.2. Market Value (US$ Mn) Forecast
9.2.6. Colorectal Cancer
9.2.6.1. Absolute $ Opportunity
9.2.6.2. Market Value (US$ Mn) Forecast
9.2.7. Others
9.2.7.1. Absolute $ Opportunity
9.2.7.2. Market Value (US$ Mn) Forecast
9.3. Market Attractiveness Analysis, By Disease Indication
10. Global Liquid Biopsy Market Analysis, By Region
10.1. Introduction
10.1.1. Y-o-Y Growth Projections, By Region
10.1.2. Market Share & Basis Point (BPS) Analysis, By Region
10.2. Market Forecast, By Region
10.2.1. North America Market Value (US$ Mn) Forecast
10.2.2. Latin America Market Value (US$ Mn) Forecast
10.2.3. Western Europe Market Value (US$ Mn) Forecast
10.2.4. Eastern Europe Market Value (US$ Mn) Forecast
10.2.5. APEJ Market Value (US$ Mn) Forecast
10.2.6. Japan Market Value (US$ Mn) Forecast
10.2.7. Middle East and Africa Market Value (US$ Mn) Forecast
10.3. Regional Attractiveness Analysis
11. North America Liquid Biopsy Market Analysis
11.1. Introduction
11.1.1. Y-o-Y Growth Projections, By Country
11.1.2. Market Share & Basis Point (BPS) Analysis, By Country
11.2. Key Trends
11.3. North America Market Forecast
11.3.1. Market Value (US$ Mn) Forecast, By Country
11.3.1.1. U.S. Absolute $ Opportunity
11.3.1.2. Canada Absolute $ Opportunity
11.3.2. Market Value (US$ Mn) Forecast, By Sample Type
11.3.2.1. Blood
11.3.2.2. Urine
11.3.2.3. Others (Plasma, Saliva, CSF)
11.3.3. Market Value (US$ Mn) Forecast, By Marker Type
11.3.3.1. CTCs (circulating tumor cells)
11.3.3.2. ctNA (circulating tumor nucleic acids)
11.3.3.3. Exosomes
11.3.4. Market Value (US$ Mn) Forecast, By End User
11.3.4.1. Hospitals
11.3.4.2. Academic Institutes
11.3.4.3. Cancer Institutes
11.3.4.4. Diagnostic Centers
11.3.5. Market Value (US$ Mn) Forecast, By Disease Indication
11.3.5.1. Lung Cancer
11.3.5.2. Leukemia
11.3.5.3. Gastrointestinal Cancer
11.3.5.4. Breast Cancer
11.3.5.5. Prostate Cancer
11.3.5.6. Colorectal Cancer
11.3.5.7. Others
11.5. Market Attractiveness Analysis
11.5.1. By Country
11.5.2. By Sample Type
11.5.3. By Disease Indication
11.5.4. By Marker Type
11.5.5. By End User
11.6. Drivers & Restraints: Impact Analysis
12. Latin America Liquid Biopsy Market Analysis
12.1. Introduction
12.1.1. Y-o-Y Growth Projections, By Country
12.1.2. Market Share & Basis Point (BPS) Analysis, By Country
12.2. Key Trends
12.3. Latin America Market Forecast
12.3.1. Market Value (US$ Mn) Forecast, By Country
12.3.1.1. Brazil Absolute $ Opportunity
12.3.1.2. Mexico Absolute $ Opportunity
12.3.1.3. Rest of Latin America Absolute $ Opportunity
12.3.2. Market Value (US$ Mn) Forecast, By Sample Type
12.3.2.1. Blood
12.3.2.2. Urine
12.3.2.3. Others (Plasma, Saliva, CSF)
12.3.3. Market Value (US$ Mn) Forecast, By Marker Type
12.4.3.1. CTCs (circulating tumor cells)
12.4.3.2. ctNA (circulating tumor nucleic acids)
12.4.3.3. Exosomes
12.3.4. Market Value (US$ Mn) Forecast, By End User
12.3.4.1. Hospitals
12.3.4.2. Academic Institutes
12.3.4.3. Cancer Institutes
12.3.4.4. Diagnostic Centers
12.3.5. Market Value (US$ Mn) Forecast, By Disease Indication
12.3.5.1. Lung Cancer
12.3.5.2. Leukemia
12.3.5.3. Gastrointestinal Cancer
12.3.5.4. Breast Cancer
12.3.5.5. Prostate Cancer
12.3.5.6. Colorectal Cancer
12.3.5.7. Others
12.4. Market Attractiveness Analysis
12.4.1. By Country
12.4.2. By Sample Type
12.4.3. By Disease Indication
12.4.4. By Marker Type
12.4.5. By End User
12.5. Drivers & Restraints: Impact Analysis
13. Western Europe Liquid Biopsy Market Analysis
13.1. Introduction
13.1.1. Y-o-Y Growth Projections, By Country
13.1.2. Market Share & Basis Point (BPS) Analysis, By Country
13.2. Key Trends
13.3. Western Europe Market Forecast
13.3.1. Market Value (US$ Mn) Forecast, By Country
13.3.1.1. Germany Absolute $ Opportunity
13.3.1.2. France Absolute $ Opportunity
13.3.1.3. U.K. Absolute $ Opportunity
13.3.1.4. Spain Absolute $ Opportunity
13.3.1.5. Italy Absolute $ Opportunity
13.3.1.6. Rest of Western Europe Absolute $ Opportunity
13.3.2. Market Value (US$ Mn) Forecast, By Sample Type
13.4.2.1. Blood
13.4.2.2. Urine
13.3.2.3. Others (Plasma, Saliva, CSF)
13.3.3. Market Value (US$ Mn) Forecast, By Marker Type
13.3.3.1. CTCs (circulating tumor cells)
13.3.3.2. ctNA (circulating tumor nucleic acids)
13.3.3.3. Exosomes
13.3.4. Market Value (US$ Mn) Forecast, By End User
13.3.4.1. Hospitals
13.3.4.2. Academic Institutes
13.3.4.3. Cancer Institutes
13.3.4.4. Diagnostic Centers
13.3.5. Market Value (US$ Mn) Forecast, By Disease Indication
13.3.5.1. Lung Cancer
13.4.5.2. Leukemia
13.4.5.3. Gastrointestinal Cancer
13.4.5.4. Breast Cancer
13.4.5.5. Prostate Cancer
13.4.5.6. Colorectal Cancer
13.4.5.7. Others
13.4. Market Attractiveness Analysis
13.4.1. By Country
13.4.2. By Sample Type
13.4.3. By Disease Indication
13.4.4. By Marker Type
13.4.5. By End User
13.5. Drivers & Restraints: Impact Analysis
14. Eastern Europe Liquid Biopsy Market Analysis
14.1. Introduction
14.1.1. Y-o-Y Growth Projections, By Country
14.1.2. Market Share & Basis Point (BPS) Analysis, By Country
14.2. Key Trends
14.3. Eastern Europe Market Forecast
14.3.1. Market Value (US$ Mn) Forecast, By Country
14.3.1.1. Russia Absolute $ Opportunity
14.3.1.2. Poland Absolute $ Opportunity
14.3.1.3. Rest of Eastern Europe Absolute $ Opportunity
14.3.2. Market Value (US$ Mn) Forecast, By Sample Type
14.3.2.1. Blood
14.3.2.2. Urine
14.3.2.3. Others (Plasma, Saliva, CSF)
14.4.3. Market Value (US$ Mn) Forecast, By Marker Type
14.4.3.1. CTCs (circulating tumor cells)
14.4.3.2. ctNA (circulating tumor nucleic acids)
14.4.3.3. Exosomes
14.4.4. Market Value (US$ Mn) Forecast, By End User
14.4.4.1. Hospitals
14.4.4.2. Academic Institutes
14.4.4.3. Cancer Institutes
14.4.4.4. Diagnostic Centers
14.4.5. Market Value (US$ Mn) Forecast, By Disease Indication
14.4.5.1. Lung Cancer
14.4.5.2. Leukemia
14.4.5.3. Gastrointestinal Cancer
14.4.5.4. Breast Cancer
14.4.5.5. Prostate Cancer
14.4.5.6. Colorectal Cancer
14.4.5.7. Others
14.5. Market Attractiveness Analysis
14.5.1. By Country
14.5.2. By Sample Type
14.5.3. By Disease Indication
14.5.4. By Marker Type
14.5.5. By End User
15. APEJ Liquid Biopsy Market Analysis
15.1. Introduction
15.1.1. Y-o-Y Growth Projections, By Country
15.1.2. Market Share & Basis Point (BPS) Analysis, By Country
15.2. Key Trends
15.3. APEJ Market Forecast
15.3.1. Market Value (US$ Mn) Forecast, By Country
14.3.1.1. China Absolute $ Opportunity
14.3.1.2. India Absolute $ Opportunity
14.3.1.3. Australia & New Zealand Absolute $ Opportunity
14.3.1.4. ASEAN Absolute $ Opportunity
14.3.1.5. Rest of APEJ Absolute $ Opportunity
15.3.2. Market Value (US$ Mn) Forecast, By Sample Type
15.3.2.1. Blood
15.3.2.2. Urine
15.3.2.3. Others (Plasma, Saliva, CSF)
15.4.3. Market Value (US$ Mn) Forecast, By Marker Type
15.4.3.1. CTCs (circulating tumor cells)
15.4.3.2. ctNA (circulating tumor nucleic acids)
15.4.3.3. Exosomes
15.4.4. Market Value (US$ Mn) Forecast, By End User
15.4.4.1. Hospitals
15.4.4.2. Academic Institutes
15.4.4.3. Cancer Institutes
15.4.4.4. Diagnostic Centers
15.4.5. Market Value (US$ Mn) Forecast, By Disease Indication
15.4.5.1. Lung Cancer
15.4.5.2. Leukemia
15.4.5.3. Gastrointestinal Cancer
15.4.5.4. Breast Cancer
15.4.5.5. Prostate Cancer
15.4.5.6. Colorectal Cancer
15.4.5.7. Others
15.5. Market Attractiveness Analysis
15.5.1. By Country
15.5.2. By Sample Type
15.5.3. By Disease Indication
15.5.4. By Marker Type
15.5.5. By End User
15.6. Drivers & Restraints: Impact Analysis
16. Japan Liquid Biopsy Market Analysis
16.1. Introduction
16.2. Key Trends
16.3. Japan Market Forecast
16.3.1. Market Value (US$ Mn) Forecast, By Sample Type
16.3.1.1. Blood
16.3.1.2. Urine
16.4.1.3. Others (Plasma, Saliva, CSF)
16.3.2. Market Value (US$ Mn) Forecast, By Marker Type
16.3.2.1. CTCs (circulating tumor cells)
16.3.2.2. ctIndication (circulating tumor nucleic acids)
16.3.2.3. Exosomes
16.3.3. Market Value (US$ Mn) Forecast, By End User
16.3.3.1. Hospitals
16.3.3.2. Academic Institutes
16.3.3.3. Cancer Institutes
16.3.3.4. Diagnostic Centers
16.3.4. Market Value (US$ Mn) Forecast, By Disease Indication
16.3.4.1. Lung Cancer
16.3.4.2. Leukemia
16.3.4.3. Gastrointestinal Cancer
16.3.4.4. Metastatic Breast Cancer
16.3.4.5. Metastatic Prostate Cancer
16.3.4.6. Metastatic Colorectal Cancer
16.3.4.7. Others
16.4. Market Attractiveness Analysis
16.4.1. By Sample Type
16.4.2. By Disease Indication
16.4.3. By Marker Type
16.4.4. By End User
16.5. Drivers & Restraints: Impact Analysis
17. Middle East and Africa Liquid Biopsy Market Analysis
17.1. Introduction
17.1.1. Y-o-Y Growth Projections, By Country
17.1.2. Market Share & Basis Point (BPS) Analysis, By Country
17.2. Key Trends
17.3. Middle East and Africa Market Forecast
17.3.1. Market Value (US$ Mn) Forecast, By Country
17.3.1.1. GCC Countries Absolute $ Opportunity
17.3.1.2. South Africa Absolute $ Opportunity
17.3.1.3. Rest of MEA Absolute $ Opportunity
17.3.2. Market Value (US$ Mn) Forecast, By Sample Type
17.3.2.1. Blood
17.3.2.2. Urine
17.3.2.3. Others (Plasma, Saliva, CSF)
17.3.3. Market Value (US$ Mn) Forecast, By Marker Type
17.3.3.1. CTCs (circulating tumor cells)
17.3.3.2. ctNA (circulating tumor nucleic acids)
17.3.3.3. Exosomes
17.3.4. Market Value (US$ Mn) Forecast, By End User
17.3.4.1. Hospitals
17.3.4.2. Academic Institutes
17.3.4.3. Cancer Institutes
17.3.4.4. Diagnostic Centers
17.3.5. Market Value (US$ Mn) Forecast, By Disease Indication
17.3.5.1. Lung Cancer
17.3.5.2. Leukemia
17.3.5.3. Gastrointestinal Cancer
17.3.5.4. Metastatic Breast Cancer
17.3.5.5. Metastatic Prostate Cancer
17.3.5.6. Metastatic Colorectal Cancer
17.3.5.7. Others
17.4. Market Attractiveness Analysis
17.4.1. By Country
17.4.2. By Sample Type
17.4.3. By Disease Indication
17.4.4. By Marker Type
17.4.5. By End User
17.5. Drivers & Restraints: Impact Analysis
18. Competition Landscape
18.1. Competition Dashboard
18.2. Company Profiles Inclusions
18.2.1. Revenue
18.2.2. Products/Brand Offerings
18.2.3. Key developments
18.2.4. SWOT Analysis
18.3. Company Profiled
18.3.1. BIOCEPT, INC.
18.3.2. Qiagen N.V.
18.3.3. Trovagene, Inc
18.3.4. Janssen Global Services, LLC
18.3.5. MDxHealth SA
18.3.6. Natera, Inc
18.3.7. F. Hoffmann-La Roche Ltd
18.3.8. Silicon Biosystems
18.3.9. Pathway Genomics Corporation
18.3.10. Sysmex Corporation

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report